<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-E143B7FU</identifier><date>2020</date><creator>Reberšek, Martina</creator><relation>documents/doc/E/URN_NBN_SI_doc-E143B7FU_001.pdf</relation><relation>documents/doc/E/URN_NBN_SI_doc-E143B7FU_001.txt</relation><format format_type="issue">3</format><format format_type="volume">54</format><format format_type="type">article</format><format format_type="extent">str. 272-277, II</format><identifier identifier_type="DOI">10.2478/raon-2020-0031</identifier><identifier identifier_type="ISSN">1318-2099</identifier><identifier identifier_type="COBISSID">14125315</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-E143B7FU</identifier><language>eng</language><publisher>Association of Radiology and Oncology</publisher><source>Radiology and oncology (Ljubljana)</source><rights>BY</rights><subject language_type_id="slv">biološki označevalci</subject><subject language_type_id="slv">kolorektalni rak</subject><subject language_type_id="slv">metastaze</subject><title>Consensus molecular subtypes (CMS) in metastatic colorectal cancer</title><title>personalized medicine decision</title></Record>